https://blog.athleticsmd.org/eloralintide-plus-tirzepatide-what-the-easd-2026-phase-2b-data-showAthleticsMD Clinical Desken2026-10-05T10:30:35.247ZEloralintide plus tirzepatide: what the EASD 2026 phase 2b data showhttps://blog.athleticsmd.org/tirzepatide-without-insurance-what-drives-the-costAthleticsMD Clinical Desken2026-10-05T10:00:35.240ZTirzepatide without insurance: what drives the costhttps://blog.athleticsmd.org/nih-funds-a-4-million-trial-on-why-weight-returns-after-stopping-glp-1-drugsAthleticsMD Clinical Desken2026-10-04T10:30:22.149ZNIH funds a $4 million trial on why weight returns after stopping GLP-1 drugshttps://blog.athleticsmd.org/resistance-training-for-sarcopenia-a-24-trial-meta-analysis-on-dose-and-clinicalAthleticsMD Clinical Desken2026-10-04T10:00:22.133ZResistance training for sarcopenia: a 24-trial meta-analysis on dose and clinical benefit